SSR Health LLC’s founder and general manager is Richard Evans, formerly of Sanford C. Bernstein and Roche. Richard founded SSR LLC in May of 2009, a boutique investment research firm that now covers Healthcare, Technology Media and Telecommunications (TMT), Financials, Consumer, and Industrials (www.ssrllc.com). SSR Health LLC is the healthcare ‘sleeve’ of SSR LLC
Before founding SSR, Richard authored Health and Capital, an analysis of the US healthcare system and prospects for its reform. Health and Capital can be read in its entirety at: www.healthandcapital.com. During this period Richard also developed and patented a cost-effective injection device intended to ease the preparation and delivery of injectable products that require admixture before injection (US patent 8,353,866)
From 1998 until 2006, Richard covered Major Pharmaceuticals as a Senior Analyst at Sanford C. Bernstein. During his tenure he was ranked first by both Institutional Investor and Bloomberg Markets for drug stock selection, and was selected as one of the top 20 stock pickers globally across all large-cap industries, also by Bloomberg Markets
From 1991 until 1998, Richard was a member of senior management at Roche, serving most recently as vice president, Business Policy and Account Management. In this capacity, he was responsible for Roche’s commercial interactions with large organized buyers such as hospitals, hospital purchasing groups, managed-care organizations and governments. His responsibilities also included those areas of the company which define and support account interactions, namely account management, customer marketing, pricing, contract administration, pharmacoeconomics, and distribution. During his seven years at Roche, Richard also served as the head of Business Development and Strategic Planning, and as product director for the company’s injectable anesthetics. He earned a doctorate in Veterinary Medicine from North Carolina State University in 1988 and a master’s of Public and Private Management from Yale University in 1991
Scott Hinds is an experienced healthcare industry analyst, economist and a co-architect of the Hidden Pipeline platform. Scott was on the Equity Capital Markets team at Lehman Brothers, where he worked on IPOs, secondary offerings and PIPE (Private Investment in Public Equity) transactions for a broad range of healthcare, biotech and chemical companies. From 2004-2009 Scott was a strategic consultant at AVOS Life Sciences, a boutique advisory firm. He specialized in large-scale quantitative projects for major pharmaceutical companies on topics ranging from development portfolio management to maximizing total shareholder returns
Scott received his M.S. from the University of North Carolina at Chapel Hill, where he taught both graduate and undergraduate Microeconomics and Math. His degree includes a concentration in Microeconomic Theory and extensive experience in complex econometric techniques. Scott’s academic work has been published in Nature Reviews Drug Discovery and Handbook of Public Finance
Ryan Baum is a longtime analyst at SSR Health. Prior to this, he was a management strategy consultant to biopharmaceutical firms at IMS Consulting Group. Mr. Baum earned his BA in Economics, Public Policy Studies, and Philosophy from Duke University, and is a CFA charterholder.